Literature DB >> 35400354

Reduced Klebsiella pneumoniae carbapenemase producing K. pneumoniae (KPC-KP) colonization in a hematological-emergency setting during Sars-CoV-2 pandemic period.

Alessandro Laganà1, Gianluca Ferri1, Mauro Passucci1, Martina Salvatori1, Maria Laura Bisegna1, Francesca Paoletti1, Francesco Aji1, Massimo Breccia1, Gregorio Antonio Brunetti1, Giacomo Salvatore Morano1, Giorgia Annechini1, Ida Carmosino1, Maurizio Martelli1, Corrado Girmenia1.   

Abstract

Entities:  

Keywords:  KPC; Klebsiella pneumoniae; SARS CoV-2; hematologic diseases; infection control

Year:  2022        PMID: 35400354      PMCID: PMC9043629          DOI: 10.1017/ice.2022.92

Source DB:  PubMed          Journal:  Infect Control Hosp Epidemiol        ISSN: 0899-823X            Impact factor:   6.520


× No keyword cloud information.
To the Editor—The coronavirus disease 2019 (COVID-19) pandemic prompted hospitals worldwide to adopt infection control measures to reduce viral transmission. As could have been predicted, during the pandemic, decreases in the incidence of other notifiable infectious diseases have been reported worldwide. Although an increase of multidrug-resistant infections diffusion has been reported in COVID-19 departments related to the intensity of care, in COVID-19–free departments COVID-19–associated interventions may have led to a favorable change in transmission dynamics involving healthcare-associated pathogens. For several years, in view of the wide diffusion of Klebsiella pneumoniae carbapenemase–producing K. pneumoniae (KPC-KP), active surveillance to detect its spread and the application of infection control measures have been implemented at the hematology departments and the outpatient hematologic emergency unit (HEU) of the AOU Policlinico Umberto I of Rome. Nevertheless, although an improved outcome of KPC-KP infections was obtained, the bacteria continued to spread widely. We defined primary colonization as cases with a known history for KPC-KP colonization in the previous 3 months or rectal swab positive for KPC-KP at admission. Patients with a negative history for KPC-KP and with a negative rectal swab at admission, when discovered to be colonized by KPC-KP during the hospitalization, were considered secondary colonization cases. From March 9, 2020, according to COVID-19 national government and hospital guidelines, intensified infection control measures took place in the hematology departments and HEU of our Institute to prevent patients with hematological diseases and healthcare personnel from becoming infected by severe acute respiratory coronavirus virus 2 (SARS-CoV-2) as well as to guarantee continuity of care in a COVID-19–free setting. A reduction of KPC-KP diffusion since March 2020 was observed at the hematology departments of our institution. The colonization rate in hospitalized patients dropped from 52.5% in November 2019–February 2020 to 15.5% in March–August 2020 (P < .0001) and secondary colonization fell from 27.5% to 8% during these periods (P = .0003). Similarly, we observed that these interventions led to a progressive decrease in the frequency of KPC-KP colonization transmission also among patients admitted to the HEU. To confirm the role of such measures in the reduction of KPC-KP transmission, we retrospectively compared the spread of KPC-KP colonization among patients hospitalized at the HEU from March 9, 2019 through March 8, 2020 (period 1) and the following year (March 9, 2020 through March 8, 2021, period 2). The same KPC-KP colonization screening (culture and real-time PCR assay on rectal swab at hospital admission and weekly during hospitalization) was applied during the 2 periods. During the 2 periods, 3,760 patients acceded to the HEU (1,755 in period 1 and 2005 in period 2), and 404 of these were hospitalized in the HEU ward [209 (11.8%) in period 1 and 195 (9.8%) in period 2]. These 404 hospitalized patients represented the study population. Patient characteristics (age, sex, underlying hematologic disease, hematologic disease stage) were comparable in the 2 periods. The reason for hospital admission was an infectious complication in 112 cases (53.6%) in period 1 and for 90 cases (46.1%) in period 2 (P = .16). In period 1, the mean days of hospitalization was 11 (median, 8; range, 2–42) and in period 2, the mean days of hospitalization was 10 (mean, 8; range, 2–59; P = .12). Overall, 35 cases of KPC-KP colonization were documented: 24 cases of primary colonization and 11 cases of secondary colonization (Fig. 1). Of the 11 secondary colonization cases, 10 were observed in the period 1 and the last one was observed in the first semester of the period 2. In the second semester of period 2, just 2 cases of primary colonization were detected and no case of secondary colonization occurred. All of the cases of secondary colonization concerned patients hospitalized for >8 days: 10 (9.8%) of 102 in period 1 versus 1 (1.1%) of 94 in period 2 (P = .01). Overall, in period 2 we observed a nonsignificant 25.6% reduction in the total KPC-KP primary colonization cases (P = .53). However, we observed a significant reduction in the second semester of the period 2 and a 90% reduction in the KPC-KP secondary colonization cases (P = .01). The reduction of cases of KPC-KP colonization cannot be attributed to a lower intensity of monitoring strategy, which was strictly adhered to during period 2.
Fig. 1.

Distribution of KPC-KP colonization cases in a pre–COVID-19 period and in a COVID-19 period at a hematologic emergency unit.

Distribution of KPC-KP colonization cases in a pre–COVID-19 period and in a COVID-19 period at a hematologic emergency unit. Despite the application of infection control measures, nosocomial transmission of KPC-KP represented an unsolved problem along the last decade at our institution. Since March 2020, an important reduction of KPC-KP cases has been observed at the hematology departments, which has resulted in the progressive reduction of cases of colonization in discharged patients who eventually attended the HEU. Thus, few cases of primary colonization were observed at the HEU during the second half of period 2. The COVID-19–related infection control measures led to decreased spread of KPC-KP, with a 90% reduction of secondary cases at the HEU even though this service is characterized by unpredictable and intensive care activities with high infectious risk. Infection control measures for KPC-KP are similar to those implemented during the COVID-19 pandemic. However, according to our experience, the infection control procedures recommended for the prevention of nosocomial infections have been more effective during the COVID-19 period than in the past. The concern about being infected by SARS-CoV-2 or about transmitting it to patients and/or family members has probably strengthened compliance with certain measures, such as hand hygiene and social distancing, by healthcare personnel and patients themselves. In conclusion, the strategies that we put in place in our institution, including the HEU dedicated to outpatients, successfully prevented the transmission of SARS-CoV-2 to hospitalized patients and avoided the horizontal transmission of KPC-KP.
  10 in total

1.  Transmission of Klebsiella pneumoniae carbapenemase (KPC)-producing Klebsiella pneumoniae: the role of infection control.

Authors:  Constantinos Tsioutis; Vanessa M Eichel; Nico T Mutters
Journal:  J Antimicrob Chemother       Date:  2021-01-29       Impact factor: 5.790

2.  COVID-19 in Patients with Hematologic Disorders Undergoing Therapy: Perspective of a Large Referral Hematology Center in Rome.

Authors:  Corrado Girmenia; Giuseppe Gentile; Alessandra Micozzi; Luigi Petrucci; Francesco Malaspina; Alessio Di Prima; Erminia Baldacci; Simona Bianchi; Pellegrina Pugliese; Ombretta Turriziani; Guido Antonelli; Vincenzo Tombolini; Robin Foà; Maurizio Martelli
Journal:  Acta Haematol       Date:  2020-09-15       Impact factor: 2.195

3.  Impact of the COVID-19 pandemic and associated non-pharmaceutical interventions on other notifiable infectious diseases in Germany: An analysis of national surveillance data during week 1-2016 - week 32-2020.

Authors:  Alexander Ullrich; Madlen Schranz; Ute Rexroth; Osamah Hamouda; Lars Schaade; Michaela Diercke; T Sonia Boender
Journal:  Lancet Reg Health Eur       Date:  2021-06-19

4.  Reduced transmission of Klebsiella pneumoniae carbapenemase-producing K. pneumoniae (KPC-KP) in patients with haematological malignancies hospitalized in an Italian hospital during the COVID-19 pandemic.

Authors:  Alessandra Micozzi; Giovanni Manfredi Assanto; Laura Cesini; Clara Minotti; Claudio Cartoni; Saveria Capria; Giulia Ciotti; Danilo Alunni Fegatelli; Livia Donzelli; Maurizio Martelli; Giuseppe Gentile
Journal:  JAC Antimicrob Resist       Date:  2021-11-17

5.  Protective effect of SARS-CoV-2 preventive measures against ESKAPE and Escherichia coli infections.

Authors:  Rita Gaspari; Giorgia Spinazzola; Luciana Teofili; Alfonso W Avolio; Barbara Fiori; Gian M Maresca; Teresa Spanu; Nicola Nicolotti; Gennaro De Pascale; Massimo Antonelli
Journal:  Eur J Clin Invest       Date:  2021-10-11       Impact factor: 4.686

Review 6.  The interface between COVID-19 and bacterial healthcare-associated infections.

Authors:  Ronan F O'Toole
Journal:  Clin Microbiol Infect       Date:  2021-06-07       Impact factor: 8.067

7.  Carbapenem-resistant Klebsiella pneumoniae in high-risk haematological patients: factors favouring spread, risk factors and outcome of carbapenem-resistant Klebsiella pneumoniae bacteremias.

Authors:  Alessandra Micozzi; Giuseppe Gentile; Clara Minotti; Claudio Cartoni; Saveria Capria; Daniele Ballarò; Stefania Santilli; Emanuele Pacetti; Sara Grammatico; Giampaolo Bucaneve; Robin Foà
Journal:  BMC Infect Dis       Date:  2017-03-10       Impact factor: 3.090

8.  Spread of hypervirulent multidrug-resistant ST147 Klebsiella pneumoniae in patients with severe COVID-19: an observational study from Italy, 2020-21.

Authors:  Marco Falcone; Giusy Tiseo; Gabriele Arcari; Alessandro Leonildi; Cesira Giordano; Sara Tempini; Giulia Bibbolino; Roberto Mozzo; Simona Barnini; Alessandra Carattoli; Francesco Menichetti
Journal:  J Antimicrob Chemother       Date:  2022-03-31       Impact factor: 5.758

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.